Xbrane in brief


Xbrane Biopharma AB is a biotechnology company that develops biosimilars, ie. follow-up drugs on subsequently approved biological drugs that can be introduced at a lower price after the patent expires for the original drug. Xbrane has a patented platform techology that priovides a lower production cost for bilological drugs compared with competing systems. Xbrane has a team with the expertise to take biosimilars from the cell line to approval with extensive collective experience from drug development. Xbrane has its head office and development lab on Campus Solna, just outside Stockholm. Xbrane has been listed on Nasdaq Stockholm since September 2019, with ticker XBRANE.

Purpose-driven organization


Biological drugs have revolutionized the treatment of many diseases, for example eye diseases such as age-related macular degeneration, autoimmune diseases such as rheumatoid arthritis, psoriasis and cancer. The only problem is that they are so expensive that it creates a problem around availability. In the USA, for example, biological drugs account for 40% of the country's drug costs, while only 2% of the population take part in the treatment. This is unsustainable and inconsistent with the WHO Constitution which states that "... the highest attainable level of health is a human right of all individuals." The goal and meaning of our work is to bring about change and eliminate these inequalities in health globally. Xbrane is a purpose-driven organization, where this purpose permeates everything we do and gives us the inspiration and motivation to drive the development of our drug candidates forward.

Our strategy


Xbrane’s goal is to become a world-leading biosimilar developer with a broad product portfolio and the lowest production cost for each molecule. Xbrane´’s strategy is based on the following three cornerstones;


1

Patented technology platforms and leading expertise

Xbranes competitive advantage is its efficiency in development and production of high quality biosimilars meeting the requirements of regulatory authorities globally. This is based on Xbranes patented technological platform with higher yields in protein production compared to standard systems as well as in built up capabilities within the critical areas of biosimilar development. Xbrane has a team of world leading scientists within microbiology, fermentation, purification and analytics and professionals with long experience from the pharmaceutical industry in regulatory, clinical and commercial supply chain. To maintain its competitive advantage Xbrane is continuously investing into strengthening and expanding its technological platform and its team – always with the focus on being the leading biosimilar developer globally when it comes to development and production efficiency.

2

High quality and cost efficient niche products

Xbrane selects products to develop on the basis of a thorough analysis of multiple parameters such as originator patent expiration timing and sales projection, product economics, expected competition and suitability for Xbranes technological plattform.  Xbrane has selected to focus on biosimilar opportunities with limited competition. The focus for the development is to develop products which meet the high level of regulatory requirements for quality at the lowest possible production cost. Xbrane’s patented technology constitutes the basis for cost-effective production, but the focus is also on other aspects that affect cost such as fermentation and purification protocol, selection of contract manufacturer and administration system.

3

Establish networks of locally strong sales and distribution partners

Xbrane is gradually developing a network of local and regional collaborative partners for sales and marketing of its products. The aim is to use this network to enable launch of the leading product candidates Xlucane and Spherotide as well as additional products over time. It is critical for Xbrane to establish partners that have a strong local presence and that can realise the full sales potential of the respective products in their market.